Free Trial

DiaMedica Therapeutics (DMAC) Earnings Date, Estimates & Call Transcripts

DiaMedica Therapeutics logo
$6.25 +0.20 (+3.31%)
Closing price 04:00 PM Eastern
Extended Trading
$6.25 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

DiaMedica Therapeutics Earnings Summary

DiaMedica Therapeutics issued Q4 2025 earnings on March 30, 2026, reporting an EPS of -$0.17, which hit the consensus estimate of -$0.17. Quarterly revenue was reported to be ($0.03) million, below the consensus estimate of $13.50 million. With a trailing EPS of -$0.70, DiaMedica Therapeutics' earnings are expected to grow next year, from ($0.84) to ($0.75) per share.

Upcoming
Earnings Date
May. 6After Market ClosesConfirmed
Consensus EPS
(Mar. 30)
-$0.17
Actual EPS
(Mar. 30)
-$0.17
Actual Revenue
(Mar. 30)
-$0.03M

Q4 2025 Earnings Resources

DMAC Upcoming Earnings

DiaMedica Therapeutics' Q1 2026 earnings is scheduled for Wednesday, May 6, 2026, with a conference call scheduled on Thursday, May 7, 2026 at 8:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Get DiaMedica Therapeutics Earnings Alerts

Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DiaMedica Therapeutics and other key companies, straight to your inbox.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.
Skip Charts & View Estimated and Actual Earnings Data

DMAC Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

DiaMedica Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20261-$0.17-$0.17-$0.17
Q2 20261-$0.18-$0.18-$0.18
Q3 20261-$0.19-$0.19-$0.19
Q4 20261-$0.21-$0.21-$0.21

DiaMedica Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails
5/6/2026
(Confirmed)
--------
3/30/2026Q4 2025-$0.17-$0.17--$0.17$13.50M-$0.03M
11/12/2025Q3 2025-$0.15-$0.17 -$0.02-$0.17--
8/12/2025Q2 2025-$0.18-$0.18--$0.18--
5/13/2025Q1 2025-$0.18-$0.18--$0.18--
3/17/2025Q4 2024-$0.17-$0.18 -$0.01-$0.18--
8/7/2024Q2 2024-$0.16-$0.13+$0.03-$0.13--
5/8/2024Q1 2024-$0.16-$0.14+$0.02-$0.14--

Data powered by Fiscal.ai.

DiaMedica Therapeutics Earnings - Frequently Asked Questions

DiaMedica Therapeutics has confirmed that its next quarterly earnings data will be published on Wednesday, May 6th, 2026. Learn more on DMAC's earnings history.

In the previous quarter, DiaMedica Therapeutics (NASDAQ:DMAC) reported ($0.17) earnings per share (EPS) to hit the analysts' consensus estimate of ($0.17). Learn more on analysts' earnings estimate vs. DMAC's actual earnings.

The conference call for DiaMedica Therapeutics' latest earnings report can be listened to online.
Listen to Conference Call

The conference call transcript for DiaMedica Therapeutics' latest earnings report can be read online.
Read Transcript

DiaMedica Therapeutics (NASDAQ:DMAC) has a recorded net income of -$32.77 million. DMAC has generated -$0.70 earnings per share over the last four quarters.

DiaMedica Therapeutics' earnings are expected to grow from ($0.84) per share to ($0.75) per share in the next year.


This page (NASDAQ:DMAC) was last updated on 5/5/2026 by MarketBeat.com Staff.
From Our Partners